PMID- 31156383
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220408
IS  - 1662-5099 (Print)
IS  - 1662-5099 (Electronic)
IS  - 1662-5099 (Linking)
VI  - 12
DP  - 2019
TI  - Elevated Serum and Cerebrospinal Fluid CD138 in Patients With 
      Anti-N-Methyl-d-Aspartate Receptor Encephalitis.
PG  - 116
LID - 10.3389/fnmol.2019.00116 [doi]
LID - 116
AB  - BACKGROUND: CD138 (also known as syndecan-1) is an important component of 
      endothelial cell glycocalyx, and it is reportedly involved in negative regulation 
      of various inflammatory processes. The clinical implications of circulating and 
      cerebrospinal fluid (CSF) soluble CD138 (sCD138) in patients with 
      Anti-N-methyl-d-aspartate receptor (NMDAR) encephalitis remain unclear. 
      OBJECTIVE: The aim of the current study was to investigate associations between 
      serum and CSF sCD138 levels in anti-NMDAR encephalitis patients. METHODS: The 
      participants enrolled in the study included 27 with anti-NMDAR encephalitis, 11 
      with viral meningoencephalitis, and 22 controls. At acute stage and 3 to 6-month 
      follow-up time-points, sCD138, tumor necrosis factor-alpha, matrix 
      metalloproteinase-2, and matrix metalloproteinase-9 in serum and CSF were 
      measured in all participants via enzyme-linked immunosorbent assays. RESULTS: 
      Serum and CSF levels of sCD138 were significantly increased in patients with 
      anti-NMDAR encephalitis. Furthermore, after 3-6 months of follow-up CSF sCD138 
      levels were significantly decreased in anti-NMDAR encephalitis patients. Changes 
      in sCD138 levels were significantly associated with amelioration of modified 
      Rankin Scale scores in patients with anti-NMDAR encephalitis. CONCLUSION: In 
      anti-NMDAR encephalitis patients, high circulating, and CSF sCD138 is associated 
      with inflammation and poor clinical prognosis. The present study suggests that 
      sCD138 may be an informative biomarker of inflammation in anti-NMDAR 
      encephalitis.
FAU - Zhu, Jiajia
AU  - Zhu J
AD  - Department of Neurology, Nanfang Hospital, Southern Medical University, 
      Guangzhou, China.
FAU - Li, Yongqi
AU  - Li Y
AD  - Department of Otolaryngology Head and Neck Surgery, Third Affiliated Hospital of 
      Sun Yat-sen University, Guangzhou, China.
FAU - Zheng, Dong
AU  - Zheng D
AD  - Department of Neurology, The Affiliated Brain Hospital of Guangzhou Medical 
      University, Guangzhou, China.
FAU - Wang, Zhanhang
AU  - Wang Z
AD  - Department of Neurology, 999 Brain Hospital, Guangzhou, China.
FAU - Pan, Suyue
AU  - Pan S
AD  - Department of Neurology, Nanfang Hospital, Southern Medical University, 
      Guangzhou, China.
FAU - Yin, Jia
AU  - Yin J
AD  - Department of Neurology, Nanfang Hospital, Southern Medical University, 
      Guangzhou, China.
FAU - Wang, Honghao
AU  - Wang H
AD  - Department of Neurology, Nanfang Hospital, Southern Medical University, 
      Guangzhou, China.
LA  - eng
PT  - Journal Article
DEP - 20190516
PL  - Switzerland
TA  - Front Mol Neurosci
JT  - Frontiers in molecular neuroscience
JID - 101477914
PMC - PMC6532527
OTO - NOTNLM
OT  - CD138
OT  - anti-NMDAR encephalitis
OT  - cerebrospinal fluid
OT  - cytokine
OT  - modified Rankin Scale
OT  - syndecan-1
EDAT- 2019/06/04 06:00
MHDA- 2019/06/04 06:01
PMCR- 2019/01/01
CRDT- 2019/06/04 06:00
PHST- 2018/12/28 00:00 [received]
PHST- 2019/04/24 00:00 [accepted]
PHST- 2019/06/04 06:00 [entrez]
PHST- 2019/06/04 06:00 [pubmed]
PHST- 2019/06/04 06:01 [medline]
PHST- 2019/01/01 00:00 [pmc-release]
AID - 10.3389/fnmol.2019.00116 [doi]
PST - epublish
SO  - Front Mol Neurosci. 2019 May 16;12:116. doi: 10.3389/fnmol.2019.00116. 
      eCollection 2019.